Patents by Inventor Vicki L. Davis

Vicki L. Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Patent number: 9370526
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: June 21, 2016
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis
  • Anti-cancer tamoxifen-melatonin hybrid ligand
    Patent number: 8785501
    Abstract: A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C2-C6 alkyl linker between the tamoxifen amine and the carbonyl of melatonin.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis, David Lapinsky
  • Combination Hormone Replacement Therapy (HRT) and Melatonin to Prevent and Treat Mammary Cancer
    Publication number: 20140171396
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis
  • In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
    Patent number: 8679511
    Abstract: An in-situ gel ophthalmic drug delivery system for estrogen containing an estrogen, a solubilizing and complexing agent, a humectant, a sorbic acid or sorbic acid based stabilizer, an optional chelating agent and gellan gum in the amount of about 0.1-0.5% w/v, optionally 0.1-0.3% w/v, of the composition.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: March 25, 2014
    Assignee: Duquesne University of the Holy Spririt
    Inventors: Moji Christianah Adeyeye, Vicki L. Davis, Uday K. Kotreka
  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Patent number: 8618083
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: December 31, 2013
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A Witt-Enderby, Vicki L Davis
  • Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand
    Publication number: 20130072539
    Abstract: A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxy-tamoxifen and also melatonin, with the tamoxifen or 5-hydroxy-tamoxifen and melatonin's being linked by an unsubstituted C2-C4 alkyl liner between the tamoxifen amine and the carbonyl of melatonin.
    Type: Application
    Filed: October 12, 2010
    Publication date: March 21, 2013
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis, David Lapinsky
  • Combination Hormone Therapy for the Eye
    Publication number: 20110319370
    Abstract: An ophthalmic instillation composition which contains melatonin and at least one other hormone, typically an estrogen but also possibly testosterone or another aromatasable androgen. The instillation is designed to reduce or eliminate cataracts in men or women to which such an ophthalmic instillation composition is administered.
    Type: Application
    Filed: June 27, 2011
    Publication date: December 29, 2011
    Applicant: DUQUESNE UNIVERSITY OF THE
    Inventors: Moji Christianah Adeyeye, Paula A Witt-Enderby, Vicki L. Davis, Udaya K. Kotreka
  • In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
    Publication number: 20110082128
    Abstract: An in-situ gel ophthalmic drug delivery system for estrogen containing an estrogen, a solubilizing and complexing agent, a humectant, a sorbic acid or sorbic acid based stabilizer, an optional chelating agent and gellan gum in the amount of about 0.1-0.5% w/v, optionally 0.1-0.3% w/v, of the composition.
    Type: Application
    Filed: September 28, 2010
    Publication date: April 7, 2011
    Inventors: Moji Christianah Adeyeye, Vicki L. Davis, Uday K. Kotreka
  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Publication number: 20110028439
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Application
    Filed: July 20, 2010
    Publication date: February 3, 2011
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis